Literature DB >> 21775465

Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin.

Raphaël Vigan1, Stuart J D Neil.   

Abstract

Tetherin (BST-2/CD317) is thought to restrict retroviral particle release by cross-linking nascent viral and cellular membranes. Unlike the Vpu proteins encoded by human immunodeficiency virus type 1 (HIV-1) group M strains (M-Vpu), those from the nonpandemic HIV-1 group O (O-Vpu) are not able to counteract tetherin activity. Here, we characterized the basis of this defect in O-Vpu. O-Vpu differs from M-Vpu in that it fails to interact with tetherin and downregulate it from the cell surface. Unlike M-Vpu, O-Vpu localizes to the endoplasmic reticulum (ER) rather than the trans-Golgi network (TGN). Interestingly M-Vpu bearing an ER retention signal at the C terminus localizes similarly to O-Vpu. While it still interacts with tetherin, it fails to promote virus release, suggesting that O-Vpu deficiency correlates with its cellular distribution in the endoplasmic reticulum as well as its failure to bind tetherin. O-Vpu-M-Vpu chimeras were designed to identify the minimal changes required to restore tetherin antagonism. While several chimeric proteins bearing residues of the M-Vpu transmembrane domain into the O-Vpu transmembrane domain recovered tetherin binding in coimmunoprecipitation studies, efficient antagonism required an additional glutamic acid-to-lysine change in the membrane-proximal hinge region of the O-Vpu cytoplasmic tail that was sufficient to abolish ER retention and permit TGN localization.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21775465      PMCID: PMC3196455          DOI: 10.1128/JVI.00479-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain.

Authors:  Andreas Hinz; Nolwenn Miguet; Ganesh Natrajan; Yoshiko Usami; Hikaru Yamanaka; Patricia Renesto; Bettina Hartlieb; Andrew A McCarthy; Jean-Pierre Simorre; Heinrich Göttlinger; Winfried Weissenhorn
Journal:  Cell Host Microbe       Date:  2010-04-22       Impact factor: 21.023

2.  HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.

Authors:  Yukie Iwabu; Hideaki Fujita; Masanobu Kinomoto; Keiko Kaneko; Yukihito Ishizaka; Yoshitaka Tanaka; Tetsutaro Sata; Kenzo Tokunaga
Journal:  J Biol Chem       Date:  2009-10-16       Impact factor: 5.157

3.  Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles.

Authors:  Kathleen Fitzpatrick; Mark Skasko; Thomas J Deerinck; John Crum; Mark H Ellisman; John Guatelli
Journal:  PLoS Pathog       Date:  2010-03-05       Impact factor: 6.823

4.  Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane.

Authors:  Jason Hammonds; Jaang-Jiun Wang; Hong Yi; Paul Spearman
Journal:  PLoS Pathog       Date:  2010-02-05       Impact factor: 6.823

5.  Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment.

Authors:  Mathieu Dubé; Bibhuti Bhusan Roy; Pierre Guiot-Guillain; Julie Binette; Johanne Mercier; Antoine Chiasson; Eric A Cohen
Journal:  PLoS Pathog       Date:  2010-04-08       Impact factor: 6.823

6.  Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains.

Authors:  Daniel Sauter; Michael Schindler; Anke Specht; Wilmina N Landford; Jan Münch; Kyeong-Ae Kim; Jörg Votteler; Ulrich Schubert; Frederic Bibollet-Ruche; Brandon F Keele; Jun Takehisa; Yudelca Ogando; Christina Ochsenbauer; John C Kappes; Ahidjo Ayouba; Martine Peeters; Gerald H Learn; George Shaw; Paul M Sharp; Paul Bieniasz; Beatrice H Hahn; Theodora Hatziioannou; Frank Kirchhoff
Journal:  Cell Host Microbe       Date:  2009-11-19       Impact factor: 21.023

7.  Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein.

Authors:  Anna Le Tortorec; Stuart J D Neil
Journal:  J Virol       Date:  2009-09-09       Impact factor: 5.103

8.  Anti-tetherin activities in Vpu-expressing primate lentiviruses.

Authors:  Su Jung Yang; Lisa A Lopez; Heiko Hauser; Colin M Exline; Kevin G Haworth; Paula M Cannon
Journal:  Retrovirology       Date:  2010-02-18       Impact factor: 4.602

9.  The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin.

Authors:  Claire Pardieu; Raphaël Vigan; Sam J Wilson; Alessandra Calvi; Trinity Zang; Paul Bieniasz; Paul Kellam; Greg J Towers; Stuart J D Neil
Journal:  PLoS Pathog       Date:  2010-04-15       Impact factor: 6.823

10.  Tetherin inhibits HIV-1 release by directly tethering virions to cells.

Authors:  David Perez-Caballero; Trinity Zang; Alaleh Ebrahimi; Matthew W McNatt; Devon A Gregory; Marc C Johnson; Paul D Bieniasz
Journal:  Cell       Date:  2009-10-30       Impact factor: 41.582

View more
  29 in total

Review 1.  HIV-1 Vpu - an ion channel in search of a job.

Authors:  Klaus Strebel
Journal:  Biochim Biophys Acta       Date:  2013-07-03

2.  Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain.

Authors:  Katharina Mack; Kathrin Starz; Daniel Sauter; Simon Langer; Frederic Bibollet-Ruche; Gerald H Learn; Christina M Stürzel; Marie Leoz; Jean-Christophe Plantier; Matthias Geyer; Beatrice H Hahn; Frank Kirchhoff
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

3.  HIV-1 Vpu mediated downregulation of CD155 requires alanine residues 10, 14 and 18 of the transmembrane domain.

Authors:  Sebastian Bolduan; Tatjana Reif; Michael Schindler; Ulrich Schubert
Journal:  Virology       Date:  2014-08-09       Impact factor: 3.616

Review 4.  Various plus unique: Viral protein U as a plurifunctional protein for HIV-1 replication.

Authors:  Andrew Soper; Guillermo Juarez-Fernandez; Hirofumi Aso; Miyu Moriwaki; Eri Yamada; Yusuke Nakano; Yoshio Koyanagi; Kei Sato
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-01

5.  Differential Control of BST2 Restriction and Plasmacytoid Dendritic Cell Antiviral Response by Antagonists Encoded by HIV-1 Group M and O Strains.

Authors:  Mariana G Bego; Lijun Cong; Katharina Mack; Frank Kirchhoff; Éric A Cohen
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

Review 6.  Multiple Inhibitory Factors Act in the Late Phase of HIV-1 Replication: a Systematic Review of the Literature.

Authors:  Jean-François Gélinas; Deborah R Gill; Stephen C Hyde
Journal:  Microbiol Mol Biol Rev       Date:  2018-01-10       Impact factor: 11.056

7.  Evidence for a different susceptibility of primate lentiviruses to type I interferons.

Authors:  Stéphanie Cordeil; Xuan-Nhi Nguyen; Gregory Berger; Stéphanie Durand; Michelle Ainouze; Andrea Cimarelli
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

8.  A comparative mutational analysis of HIV-1 Vpu subtypes B and C for the identification of determinants required to counteract BST-2/Tetherin and enhance viral egress.

Authors:  Janet L Douglas; Ying Bai; Jean K Gustin; Ashlee V Moses
Journal:  Virology       Date:  2013-04-10       Impact factor: 3.616

9.  HIV-1 Vpu affects the anterograde transport and the glycosylation pattern of NTB-A.

Authors:  Sebastian Bolduan; Philipp Hubel; Tatjana Reif; Veronika Lodermeyer; Kristin Höhne; Joëlle V Fritz; Daniel Sauter; Frank Kirchhoff; Oliver T Fackler; Michael Schindler; Ulrich Schubert
Journal:  Virology       Date:  2013-03-22       Impact factor: 3.616

10.  The size and conservation of a coiled-coil structure in the ectodomain of human BST-2/tetherin is dispensable for inhibition of HIV-1 virion release.

Authors:  Amy J Andrew; Christopher E Berndsen; Sandra Kao; Klaus Strebel
Journal:  J Biol Chem       Date:  2012-11-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.